Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security
August 25, 2017
- MHLW Council Recommends Public Knowledge-Based Applications for 2 Products Including Velcade
August 25, 2017
- MHLW Presents Steps Responding to Chuikyo Reps’ Concerns for “Willing-to-Pay Cost” Survey
August 24, 2017
- Chuikyo OKs MHLW’s Discussion Timeline on CEA, 3 Subcommittees to Hold Joint Debates
August 24, 2017
- Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
- Leftover Spinraza in 9-Million-Yen Vial Must Be Discarded, Can’t Be Saved for Next Time: MHLW Official
August 23, 2017
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
- Final Report on MID-NET’s Full Operations Published
August 22, 2017
- MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities
August 22, 2017
- Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official
August 21, 2017
- MHLW Advisory Panel to Review Budesonide Rectal Foam on Sept. 1
August 21, 2017
- 11 Firms Get Approval for Irbesartan Generics towards December Listing, including AG; 26 Flock to Crestor
August 16, 2017
- NIBIOHN to Promote Drug Discovery in Fields with Unmet Needs by Automating Target Discovery Using AI
August 15, 2017
- “Pediatric Treatment” Excluded from Appraisal Adjustment Factors in Pilot Program: Chuikyo
August 10, 2017
- MHLW Wants to Use Past Surveys, Overseas Examples for ICER Yardstick in CEA Pilot Program, Plan Draws Fire from Payers Reps: Chuikyo
August 10, 2017
- Calls Growing for Tougher Requirements to Receive Price Maintenance Premium: Chuikyo
August 10, 2017
- New Measures Needed to Ramp Up Generic Use: Chuikyo
August 10, 2017
- MHLW Orders Label Revisions for Warfarin, 3 Other APIs
August 7, 2017
- (Update) Katsunobu Kato Tapped as New Health Minister
August 4, 2017
- Clinical Research Law to Apply to “Nearly All Drug-Related Clinical Research” Funded by Drug Makers: MHLW
August 4, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…